Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
NCT04414631 · University Hospital, Basel, Switzerland · PHASE2 · terminated · last registry update 2021-11-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Aim to enroll 120 patients deemed not sufficient to show a difference in the primary outcome measure. Standard of care treatment recently changed in Switzerland adding further heterogeneity to trial population when including future participants.” | – | Registry record, University Hospital, Basel, Switzerland |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SERPING1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-07-29Also stopped (terminated): CSL Behring, C1-esterase inhibitor + Placebo (NCT03221842)
- 2022-02-04Also stopped (withdrawn): AO GENERIUM, GNR-038, 50 МЕ/ kg + GNR-038, 100 МЕ/ kg (NCT04898309)
- 2022-01-18Results posted on the registry: CSL Behring, C1-esterase inhibitor + Placebo (NCT03221842)
- 2021-05-24Phase 3 first posted: AO GENERIUM, GNR-038, 50 МЕ/ kg + GNR-038, 100 МЕ/ kg (NCT04898309)
- 2021-01-19Also stopped (terminated): TSI, LLC, M5 + C1-inhibitor (NCT01694381)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision